Mechanisms of Sorafenib Resistance in HCC Culture Relate to the Impaired Membrane Expression of Organic Cation Transporter 1 (OCT1)
DOI: https://doi.org/10.2147/jhc.s452152
2024-05-10
Journal of Hepatocellular Carcinoma
Abstract:Srinivas Chava, 1 Nergiz Ekmen, 2 Pauline Ferraris, 1 Yucel Aydin, 2 Krzysztof Moroz, 1 Tong Wu, 1 Swan N Thung, 3 Srikanta Dash 1, 2, 4 1 Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA; 2 Department of Gastroenterology and Hepatology, Tulane University Health Sciences Center, New Orleans, LA, USA; 3 Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 4 Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA Correspondence: Srikanta Dash, Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA, 70112, USA, Tel +1 504-988-2519, Fax +1 504-988-7389, Email Introduction: Sorafenib, an FDA-approved drug for advanced hepatocellular carcinoma (HCC) treatment, encounters resistance in many patients. Deciphering the mechanisms underlying sorafenib resistance is crucial for devising alternative strategies to overcome it. Aim: This study aimed to investigate sorafenib resistance mechanisms using a diverse panel of HCC cell lines. Methods: HCC cell lines were subjected to continuous sorafenib treatment, and stable cell lines (Huh 7.5 and Huh 7PX) exhibiting sustained growth in its presence were isolated. The investigation of drug resistance mechanisms involved a comparative analysis of drug-targeted signal transduction pathways (EGFR/RAF/MEK/ERK/Cyclin D), sorafenib uptake, and membrane expression of the drug uptake transporter. Results: HCC cell lines (Huh 7.5 and Huh 7PX) with a higher IC50 (10μM) displayed a more frequent development of sorafenib resistance compared to those with a lower IC50 (2– 4.8μM), indicating a potential impact of IC50 variation on initial treatment response. Our findings reveal that activated overexpression of Raf1 kinases and impaired sorafenib uptake, mediated by reduced membrane expression of organic cation transporter-1 (OCT1), contribute to sorafenib resistance in HCC cultures. Stable expression of the drug transporter OCT1 through cDNA transfection or adenoviral delivery of OCT1 mRNA increased sorafenib uptake and successfully overcame sorafenib resistance. Additionally, consistent with sorafenib resistance in HCC cultures, cirrhotic liver-associated human HCC tumors often exhibited impaired membrane expression of OCT1 and OCT3. Conclusion: Intrinsic differences among HCC cell clones, affecting sorafenib sensitivity at the expression level of Raf kinases, drug uptake, and OCT1 transporters, were identified. This study underscores the potential of HCC tumor targeted OCT1 expression to enhance sorafenib treatment response. Keywords: hepatocellular carcinoma, HCC, cholangiocarcinoma, CCA, tyrosine kinase inhibitors, TKI, organic cation transporter-1, OCT1, organic cation transporter-3, OCT3, sorafenib resistance cell lines, SR huh 7 Hepatocellular carcinoma (HCC) stands as the sixth most prevalent cancer globally and the fourth leading cause of cancer-related mortality. 1 Predominantly arising from chronic liver conditions, including cirrhosis induced by viral and non-viral factors such as alcohol and non-alcoholic fatty liver disease, HCC exhibits a rising incidence in the United States, propelled by the obesity epidemic and metabolic syndromes. 2 While early-stage HCC is amenable to curative interventions like surgical resection or liver transplantation, advanced cases present a clinical challenge. Sorafenib, an oral multi-kinase inhibitor, has gained FDA approval for treating advanced HCC, targeting RAF kinase signaling pathways pivotal in tumor progression and angiogenesis. 3 Despite its efficacy, the survival benefits for sorafenib-treated HCC patients remain modest due to prevalent resistance mechanisms. 4,5 The reasons underlying HCC resistance to sorafenib are not fully understood. Two primary resistance mechanisms—preexisting and acquired—contribute to sorafenib treatment failure. 6 Preexisting resistance manifests when tumors exhibit no response to chemotherapy from the onset, potentially involving activation of various signaling pathways such as EGFR, c-MET, IGFR, Wnt/B-catenin, or PI3K/Akt/mTOR. 7–12 Conversely, adaptive or acquired resistance occurs when tumors initially respond but later develop resistance, with mechanisms including cancer stem cells, epithelial-mesenchymal transition (EMT), platelet-tumor microenvironment interactions, hypoxia, inflammation, cytokine expression, and cellular autophagy. 13–19 Since the clinical trials using MAPK inhibitors are not providing significa -Abstract Truncated-
oncology